Autopsy report · NCT00642226

Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Due to recruiting problems and the introduction of new treatment strategies (ranibizumab and dexamethasone implant).”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year 4 months after it had already started.
Ran for about 7 years before it stopped.
34 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Helse Stavanger HF
Sponsor type: Government (non-US federal)
Conditions: Branch Retinal Vein Occlusion; Macular Edema
Interventions: Grid Laser; Vitrectomy and 20 mg triamcinolone
Participants: 34
Sites: 1
Countries: Norway

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.